Related Experiment Video

Updated: May 4, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

[Targeted therapies, prognostic and predictive factors in endocrine oncology]

S Hescot1, E Baudin1, F Borson-Chazot2

  • 1Inserm U693, Faculté de médecine Paris-Sud, Université Paris-Sud, Le Kremlin-Bicêtre, France; Médecine nucléaire et Oncologie endocrinienne, Institut Gustave-Roussy, Université Paris-Sud, Villejuif, France.

Annales D'Endocrinologie
|December 21, 2013
PubMed

Insights

Targeted therapies show promise in endocrine tumors, improving progression-free survival. However, identifying predictive biomarkers remains crucial for personalized endocrine cancer medicine.

Area of Science:

  • Endocrine oncology
  • Molecular mechanisms of tumorigenesis
  • Targeted cancer therapies

Background:

  • Understanding cancer molecular mechanisms aids targeted drug development.
  • Targeted therapies like vandetanib, cabozantinib, sorafenib, everolimus, and sunitinib show efficacy in endocrine tumors.
  • Ongoing trials investigate treatments for rare endocrine cancers, including malignant pheochromocytoma and adrenocortical carcinoma.

Purpose of the Study:

  • To review recent advances in endocrine oncology.
  • To discuss molecular targets, targeted therapies, and predictive/prognostic markers.
  • To highlight the need for predictive biomarkers in personalized endocrine cancer medicine.

Main Methods:

  • Literature review of recent advances in endocrine oncology.
  • Analysis of phase III trial data for targeted therapies in endocrine tumors.
  • Synthesis of information on molecular targets and biomarkers.

Main Results:

  • Several targeted drugs have demonstrated efficacy in improving progression-free survival for specific endocrine tumors.
  • Ongoing clinical trials are exploring new treatments for rare endocrine malignancies.
  • No specific predictive biomarker has been identified for personalized endocrine cancer treatment yet.

Conclusions:

  • Targeted therapies represent a significant advancement in endocrine oncology.
  • Further research is needed to identify predictive biomarkers for personalized cancer medicine.
  • Personalized treatment strategies are essential for improving outcomes in endocrine tumors.
Keywords:
Adrenocortical carcinomaCancer thyroïdienCorticosurrénalomeFacteur pronostiqueFacteur prédictifMalignant pheochromocytomaPancreatic neuroendocrine tumorPhéochromocytome malinPredictive markerPrognostic markerTargeted therapyThyroid carcinomaThérapie cibléeTumeur neuroendocrine du pancréas

More Related Videos

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

7.8K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

6.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
863
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Cancer Therapies02:49

Cancer Therapies

2.4K